Imbio PHA (4.0.0) vs Tempus ECG-Low EF

Imbio PHA integrates seamlessly into existing radiology workflows, providing rapid, fully-automated assessment and delivering annotated DICOM images and PDF reports directly to PACS, enhancing the radiologist's visual information and efficiency. While Tempus ECG-Low EF offers a simple binary output, it lacks a dedicated user interface and relies entirely on integration with other systems for result presentation.

Tempus ECG-Low EF leverages a widely available and inexpensive diagnostic tool (ECG) to screen for low LVEF, a critical indicator for heart failure, enabling early identification at scale for a prevalent condition. While Imbio PHA provides valuable quantitative diagnostic and risk stratification from CT imaging, Tempus's approach offers a broader and more accessible impact for initial risk identification in a larger patient population.

Both tools require direct contact for pricing, making a direct cost comparison impossible. However, Tempus ECG-Low EF gains a significant advantage from the recent CMS decision to include AI-ECG technology in its 2025 reimbursement schedule, which provides a clear pathway for reimbursement and enhances its overall value proposition and accessibility for healthcare facilities.

Both tools are FDA-cleared, HIPAA compliant, and offer BAAs, establishing a strong foundation for enterprise use. Imbio PHA explicitly provides flexible deployment options, including cloud, on-premise, or via partners, and details its integration with native DICOM tools and workflows through its Core Computing Platform (ICCP), offering greater adaptability for diverse IT infrastructures. Tempus ECG-Low EF mentions integration but with less specific detail on technical architecture and deployment flexibility.

Tempus ECG-Low EF demonstrates significant innovation by applying AI to standard, inexpensive 12-lead ECGs to detect signs of low LVEF, a critical indicator for heart failure, enabling widespread early detection and intervention. The algorithm was trained on a massive dataset of over 930,000 ECGs, and Tempus has a track record with a second FDA-cleared ECG-AI device, highlighting its leadership in this area. Imbio PHA innovates by automating complex quantitative measurements from CT, but Tempus's approach leverages a more ubiquitous and accessible modality for population-level screening.

Imbio PHA offers clear support channels via phone and email, provides user manuals and product documentation upon request, and has an online FAQ section covering clinical and technical aspects. While Tempus provides customer support for billing and general inquiries, and documentation is implied, Imbio's resources appear more explicitly structured and readily accessible for product-specific user support.